Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 (MAP4K1) Peptid
MAP4K1
Reaktivität: Human
Wirt: Synthetic
BP, WB
-
- Target Alle MAP4K1 Produkte
- MAP4K1 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 (MAP4K1))
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB)
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-MAP4K1 antibody (Catalog #: ARP46044_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Aufreinigung
- Purified
-
-
- Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Konzentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handhabung
- Avoid repeated freeze-thaw cycles.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- MAP4K1 (Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 (MAP4K1))
- Hintergrund
-
MAP4K1 belongs to the protein kinase superfamily, STE Ser/Thr protein kinase family, STE20 subfamily. MAP4K1 may play a role in the response to environmental stress. It appears to act upstream of the JUN N-terminal pathway. MAP4K1 may play a role in hematopoietic lineage decisions and growth regulation.
Alias Symbols: HPK1
Protein Interaction Partner: CRK,CRKL,GRAP2,GRB2,ABL1,BLNK,CASP3,CRK,CRKL,DAPP1,DBNL,EGFR,GRAP2,GRB2,HCLS1,LAT,LCP2,LYN,MAP3K11,MAP3K7,MAP4K1,MAP4K1,NCK1,SHC1,SYK,BLNK,CRK,CRKL,DBNL,EGFR,GRAP2,GRB2,HCLS1,LAT,MAP3K11,MAP3K7,NCK1
Protein Size: 821 - Molekulargewicht
- 90 kDa
- Gen-ID
- 11184
- NCBI Accession
- NM_001042600, NP_001036065
- UniProt
- A8MWC4
-
Sie sind hier:
